Who Paid My Doc
Jonathan Wiener
Nurse Practitioner, Critical Care Medicine Hendersonville, NC Nurse Practitioner
NPI 1033511654 CMS profile 10676087
800 Fleming St, Hendersonville, NC 28791
General payments
$583
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jonathan Wiener of Hendersonville, NC is reported in the CMS Open Payments database as having received $583 across 16 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 74th percentile of Nurse Practitioner, Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $440 | 11 | |
| 2024 | General | $67 | 2 | |
| 2023 | General | $61 | 2 | |
| 2022 | General | $14 | 1 |
Beside peers
- Jonathan Wiener
- Nurse Practitioner, Critical Care Medicine median
- Middle half of Nurse Practitioner, Critical Care Medicine
- National median
In program year 2025, general payments to Jonathan Wiener were reported at $440. Among 524 Nurse Practitioner, Critical Care Medicine profiles paid that year, the median was $119 and the middle half received between $34 and $300.
Show as a table
| Year | Jonathan Wiener | Nurse Practitioner, Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $103 | $27–$237 | $132 |
| 2022 | $14 | $125 | $44–$255 | $149 |
| 2023 | $61 | $116 | $32–$261 | $160 |
| 2024 | $67 | $122 | $32–$292 | $164 |
| 2025 | $440 | $119 | $34–$300 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
520
Drug cost
$11,867
Branded share of claims
47.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 15 | $4,649 | |
| Xarelto Rivaroxaban | Brand | 12 | $3,958 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 204 | $1,777 | |
| Prednisone | Generic | 41 | $433 | |
| Celecoxib | Generic | 36 | $314 | |
| Tramadol Hcl | Generic | 100 | $236 | |
| Meloxicam | Generic | 70 | $150 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 15 | $147 | |
| Oxycodone Hcl | Generic | 16 | $137 | |
| Ondansetron Hcl | Generic | 11 | $67 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 44 billing codesPaid by Medicare
$157,465
Medicare patients
528
Services billed
9,099
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 72% | |
| Osteoporosis | 22% | |
| Depression | 20% | |
| Ischemic heart disease | 19% | |
| Atrial fibrillation | 19% | |
| Diabetes | 16% | |
| Cancer | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 | Office | 72 | 101 | $54,192 |
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 | Office | 22 | 1,860 | $8,697 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 267 | 2,261 | $1,638 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
16 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Critical Care Medicine in North Carolina
Holly Smith
Nurse Practitioner, Critical Care Medicine · Wilmington, NC
Dwayne Bell
Nurse Practitioner, Critical Care Medicine · Holly Springs, NC
Cameron Little
Nurse Practitioner, Critical Care Medicine · Raleigh, NC
Jennifer Parrotte
Nurse Practitioner, Critical Care Medicine · Wilmington, NC
Hannah King
Nurse Practitioner, Critical Care Medicine · Raleigh, NC
Paula Simpson
Nurse Practitioner, Critical Care Medicine · Greensboro, NC
Related records
Nurse Practitioner, Critical Care Medicine in North Carolina
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in North Carolina
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.